H.C. Wainwright Now Covering Synthetic Biologics Inc (AMEX:SYN) With $1.0000 Target

May 18, 2018 - By Darrin Black

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) Logo

Why Has H.C. Wainwright Given Synthetic Biologics Inc (AMEX:SYN) a $1.0000 Price Target

In an analyst note shared with investors today, H.C. Wainwright analysts began Synthetic Biologics Inc (AMEX:SYN) coverage with Buy rating, and a $1.0000 target.

The stock increased 2.06% or $0.0051 during the last trading session, reaching $0.2525. About 122,248 shares traded. Synthetic Biologics, Inc. (AMEX:SYN) has declined 50.78% since May 18, 2017 and is downtrending. It has underperformed by 62.33% the S&P500.

Analysts await Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) to report earnings on August, 2. They expect $-0.04 EPS, down 33.33 % or $0.01 from last year’s $-0.03 per share. After $-0.02 actual EPS reported by Synthetic Biologics, Inc. for the previous quarter, Wall Street now forecasts 100.00 % negative EPS growth.

Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. The company has market cap of $32.46 million. The Company’s lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous beta-lactam antibiotics for the prevention of C. difficile infection, overgrowth of pathogenic organisms, and the emergence of antimicrobial resistance; and SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. It currently has negative earnings. The company's preclinical products include an oral formulation of the enzyme intestinal alkaline phosphatase to treat local GI disorders and systemic diseases; monoclonal antibody therapies for the prevention and treatment of pertussis; and novel discovery stage biotherapeutics for the treatment of phenylketonuria.

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.